FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 60 filers reported holding FATE THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $24,000 | +41.2% | 1,500 | 0.0% | 0.01% | +66.7% |
| Q2 2018 | $17,000 | +13.3% | 1,500 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $15,000 | -44.4% | 1,500 | -66.7% | 0.00% | 0.0% |
| Q4 2017 | $27,000 | -20.6% | 4,500 | -47.1% | 0.00% | -25.0% |
| Q3 2017 | $34,000 | +61.9% | 8,500 | +30.8% | 0.00% | +100.0% |
| Q2 2017 | $21,000 | -30.0% | 6,500 | 0.0% | 0.00% | -66.7% |
| Q1 2017 | $30,000 | – | 6,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |